臨床試驗顯示新型肺結核疫苗效力有限
New TB vaccines show limited effectiveness in clinical trial
結核病（TB）仍是一項重大的全球健康挑戰，每年造成數百萬例病例和死亡案例。
Tuberculosis (TB) remains a major global health challenge, causing millions of cases and deaths every year.
科學家長期以來一直在尋求改良型疫苗，以取代或補充擁有百年歷史的卡介苗（BCG），該疫苗對兒童效果顯著，但對成人的保護力有限。
Scientists have long sought an improved vaccine to replace or supplement the century-old BCG vaccine, which works well for children but offers limited protection for adults.
一項重大的近期研究——「PreVenTB」試驗，檢測了兩種新型疫苗候選物VPM1002和Immuvac。
A significant recent study, the PreVenTB trial, examined two new vaccine candidates, VPM1002 and Immuvac.
雖然這些疫苗被證明是安全的，但遺憾的是，牠們並未在一般人口中對標準肺結核病顯示出顯著的保護效果。
While these vaccines were proven safe, they unfortunately did not show significant protection against standard pulmonary TB in the general population.
然而，該研究提供了一些令人振奮的消息：VPM1002在預防肺外結核病方面表現成功，且初步數據表明，它對6至14歲的兒童可能特別有效。
However, the study provided some encouraging news: VPM1002 showed success in preventing extrapulmonary TB, and preliminary data suggests it might be particularly effective in children aged 6 to 14.
有趣的是，研究人員發現營養扮演著關鍵角色，因為營養不良個體的疫苗效力較低。
Interestingly, the researchers found that nutrition plays a key role, as vaccine effectiveness was lower in individuals who were underweight.
這凸顯出針對結核病的「一體適用」解決方案恐怕難以實現。
This highlights that a one-size-fits-all solution for TB is likely out of reach.
展望未來，專家建議我們需要的或許不是一種普及型疫苗，而是一種分層策略，即將疫苗接種與營養支援相結合，並針對特定年齡層或高風險族群進行防護。
Moving forward, experts suggest that instead of a universal vaccine, we may need a stratified approach, combining vaccination with nutritional support and targeting specific age groups or high-risk demographics.
雖然這些結果提醒我們結核病研究的複雜性，但終結此疾病的全球努力仍在持續，其他有前景的候選物目前正在研發中。
While these results are a reminder of the complexity of TB research, the global effort to end this disease continues with other promising candidates currently in development.
